Efficacy and safety of crizotinib in patients with ROS1 rearranged non-small cell lung cancer: a retrospective analysis

BACKGROUND: Tyrosine kinase inhibitors (TKIs) are remarkably effective in patients with non-small cell lung carcinoma (NSCLC) harboring driver gene mutations and rearrangements. Crizotinib, a small-molecule TKI, has been demonstrated to be an efficacious drug against c-ros oncogene 1-rearranged NSCL...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Thorac Dis
Hlavní autoři: Masuda, Ken, Fujiwara, Yutaka, Shinno, Yuki, Mizuno, Takaaki, Sato, Jun, Morita, Ryo, Matsumoto, Yuji, Murakami, Shuji, Goto, Yasushi, Kanda, Shintaro, Horinouchi, Hidehito, Yamamoto, Noboru, Ohe, Yuichiro
Médium: Artigo
Jazyk:Inglês
Vydáno: AME Publishing Company 2019
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6688037/
https://ncbi.nlm.nih.gov/pubmed/31463126
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2019.07.44
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky